The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
Astra ditches a Duo
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
Pivotal Claudin18.2 candidates keep coming
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
Pfizer mimics pumitamig in gastroesophageal cancers
The company will start a phase 2/3 trial of PF-08634404 in March.
CSPC looks for HER2 white space
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
OnKure is no longer the only game in town
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
Astellas makes its KRAS degrader choice
The company discontinues one of its two KRAS G12D degraders.
AbbVie scales back its GARP ambitions
After a phase 3 push the livmoniplimab plan falters.
